Skip to main content
Clinical Trials/NL-OMON48151
NL-OMON48151
Completed
Not Applicable

A phase I randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of NPT189 in healthy subjects - Study to evaluate the safety, tolerability and PK of NPT189

Proclara Biosciences, Inc.0 sites24 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Proclara Biosciences, Inc.
Enrollment
24
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Trial ended prematurely

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \- healthy males and females
  • \- 18\-65 years, inclusive
  • \- Weight \>\= 45 kg and \<\= 120 kg with a BMI of 18\.0\-32\.0 inclusive

Exclusion Criteria

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of
  • participation in another drug study within 90 days before the start of this
  • study or being a blood donor within 60 days from the start of the study. In
  • case of donating more than 1\.5 liters of blood in the 10 months prior the start
  • of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A phase I, randomised, double-blind, placebo-controlled study in patients with amyotrophic lateral sclerosis to further assess the safety and tolerability of intracerebroventricular administration of sNN0029 infusion solution.ALSLou Gehrig's disease1002930510009720
NL-OMON40611ewron Sweden AB9
Completed
Not Applicable
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, First in Man, Single Escalating Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GAL-475 in Healthy Male Volunteers and Male Subjects with Sleep Apneasleep disorderSleep apnea
NL-OMON55229eurim Pharmaceuticals Ltd.36
Completed
Phase 3
A randomized, double-blind, placebo-controlled intervention study to assess the therapeutic effect of an extensively hydrolyzed infant formula with an added synbiotic mixture in infants with atopic dermatitis.atopic dermatitiseczema1003871610040785
NL-OMON39465Danone Research - Centre for Specialised Nutrition144
Completed
Phase 2
A randomized, placebo-controlled, double-blind, parallel-group, multi-center, exploratory dose-response study to assess the efficacy and safety of different oral doses of BAY1128688 in women with symptomatic endometriosis over a 12-week treatment periodpain during intercourse ('dyspareunia') and non-cyclic pelvic pain.Well-accepted lay language synomyms for endometriosis are not known to us. Endometriosis describes the presence of endometrium elsewhere than in the lining of the uterus. It is associated with pelvic pain during menstruation called 'dysmenorrhea'10038612
NL-OMON46660Bayer5
Completed
Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas
NL-OMON48469Clementia Pharmaceuticals Inc10